CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...
On August 9, 2019, the new CTS Laboratory Information System was successfully implemented in St...
CTS lab staff recently participated in a Kaizen and determined emailed Daily Shipment Schedules to b...
We have now added a new section called the "Assay History List" to the "At A Gla...
That’s just one of the reasons that National Blood Donor Month, which has taken place each Jan...
We sincerely hope to see you at this year’s AABB Annual Meeting in Boston, MA on October 12-16...